Jiangsu Hengrui Medicine Co., Ltd.
600276.SS
$-0.04
Change (1 day)
$7.89
Year High
$4.87
Year Low
Categories
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
P/E ratio for Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)
P/E ratio as of 2023: 66.51
According to Jiangsu Hengrui Medicine Co., Ltd.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 66.51. At the end of 2022 the company had a P/E ratio of 62.80.
P/E ratio history for Jiangsu Hengrui Medicine Co., Ltd. from 1997 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 66.51 |
| 2022 | 62.80 |
| 2021 | 71.42 |
| 2020 | 93.29 |
| 2019 | 72.29 |
| 2018 | 47.97 |
| 2017 | 49.84 |
| 2016 | 34.35 |
| 2015 | 36.83 |
| 2014 | 25.74 |
| 2013 | 29.05 |
| 2012 | 24.06 |
| 2011 | 26.27 |
| 2010 | 42.68 |
| 2009 | 34.09 |
| 2008 | 32.68 |
| 2007 | 41.80 |
| 2006 | 51.77 |
| 2005 | 9.91 |
| 2004 | 11.08 |
| 2003 | 9.67 |
| 2002 | 13.86 |
| 2001 | 18.97 |
| 2000 | 32.27 |
| 1999 | 37.70 |
| 1998 | 44.76 |
| 1997 | 47.12 |